Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Happy 2018 — Here Are Our Most Read Articles in 2017


(Andrew Martin, Pixabay)

1 January 2018. Happy new year to our visitors. We want to thank the nearly 20,000 individuals who read Science & Enterprise since we started tracking the numbers through Google Analytics in April. Here are the most visited of our 539 posts in 2017, excluding the nearly 5,000 people who looked at the site’s home page. We look forward to continue reporting on more exciting stories about science for business people and enterprise for scientists in the year ahead.

11 April 2017. A joint venture between Food and Drug Administration and a developer of chip devices simulating human organs, is evaluating the chips as a way to test new drugs for toxic effects. FDA and Emulate Inc. in Boston, Massachusetts, a spin-off enterprise from the Wyss Institute for Biologically Inspired Engineering at Harvard University, will assess the ability of organs-on-chips to fulfill regulatory needs for testing drugs, as well as food, dietary supplements, and cosmetics.

10 August 2017. Researchers in the U.S., Denmark, and China devised a process with genome editing to remove viruses that prevent organs from pigs from being used for human transplants. The process is described by a team from the start-up company eGenesis Inc. in Cambridge, Massachusetts, with colleagues from Harvard University, Aarhus University in Denmark, and several institutions in China, in today’s issue of the journal Science (paid subscription required).

29 August 2017. A team of undergraduate students won first prize in a National Institutes of Health biomedical engineering contest for a headset device to diagnose early-stage Alzheimer’s disease. The engineering students at University of Maryland in College Park, who received notice of the award on Friday, are also starting a company to take their invention to market.

20 September 2017. A company developing treatments for disease by restoring the natural balance of bacteria on the skin received a patent for its acne therapy using spray-on live bacteria. The U.S. Patent and Trademark Office awarded patent number 9,738,870 on 22 August to AOBiome LLC in Cambridge, Massachusetts. The three inventors on the patent include the two company founders, David Whitlock and Spiros Jamas, and chief medical officer Larry Weiss.

30 June 2017. The U.S. Food and Drug Administration approved use of vagus nerve stimulation to treat epilepsy in children who do not respond to drug therapy as young as 4 years old. The company LivaNova PLC in London, U.K. that makes the VNS Therapy system says FDA previously set the minimum age for its vagus nerve treatments for epilepsy at 12 years.

14 August 2017. The European Patent Office announced its intent to award a patent on treatments for nerve cell damage based on the peptide thymosin beta 4. The patent will be awarded to Michael Chopp, a neuroscience researcher at Henry Ford Health System in Detroit, which licensed his discoveries to the company RegeneRx Biopharmaceuticals Inc. in Rockville, Maryland.

*     *     *

Comments are closed.